Edesa Biotech Licenses Paridiprubart to Kyorin for $12 Million Upfront

Fifty percent. That is how much Faeth Therapeutics gave up on Monday after releasing cancer data it called positive. Edesa Biotech went the other way the same morning, climbing as much as 39% on a licensing deal in Japan.

Edesa Biotech Signs $12M Upfront Japan Deal With Kyorin

Edesa Biotech (Nasdaq: EDSA) signed an exclusive license with Kyorin Pharmaceutical on November 9 covering paridiprubart in Japan for acute respiratory distress syndrome (ARDS). Edesa gets $12 million upfront and is eligible for about $134 million in development, regulatory and sales milestones, part of it in yen, plus tiered double-digit royalties.

The stock rose as much as 39% to $2.98 during Monday’s session. Benzinga put the company’s market value at about $20.6 million.

Kyorin, a Tokyo-listed drugmaker founded in 1923, pays for Japanese development and commercialization. Edesa keeps every right outside Japan and will make the product.

The deal rests on a Phase 3 study Edesa itself describes as truncated. In its 104 mechanically ventilated patients, adjusted 28-day mortality was 39% on paridiprubart versus 52% on placebo, with both arms on standard care. A broader 278-patient analysis in February put it at 24% versus 33%. Paridiprubart is investigational and not approved anywhere.

Money has been tight. Edesa held $10.3 million in cash at June 30, per its fiscal third-quarter report, then raised about $25 million in August at $5.50 per share and warrant, with warrants struck at $7.50. Before the deal, shares had lost roughly 40% in a month. The release does not say when Kyorin’s $12 million arrives.

Faeth Therapeutics Falls as Much as 50% on 33% Response Rate

Faeth Therapeutics (Nasdaq: FTH) reported preliminary Phase 2 results on November 9 for PIKTOR, an oral pairing of serabelisib and sapanisertib given with paclitaxel. In the single-arm PIK-201 study, 12 of 36 evaluable patients had a confirmed response, an objective response rate (tumors shrinking past a set threshold, confirmed on a later scan) of 33%. Patients with a PIK3CA mutation hit 44%, seven of 16.

Shares traded down as much as 50% to $11.01. The company was worth about $568 million going in.

Expectations did the damage. Some investors had looked for a response rate near 40%. TD Cowen kept its Buy rating, with analyst Tara Bancroft noting the results beat a chemotherapy benchmark of roughly 15% response and three to four months of progression-free survival. Faeth’s preliminary median was 7.4 months across 42 treated patients.

Two patients, or 5%, stopped treatment over drug-related side effects. Hyperglycemia showed up in 12% and mouth sores in 21%. No treatment-related deaths were reported.

Faeth is new to trading under its own name. Sensei Biotherapeutics acquired it in a stock-for-stock deal in February, alongside a $200 million private placement at $13.85 per share on an as-converted basis. Former Faeth holders were set to own about 89.3% of the combined company before that placement, which added roughly 14.4 million more as-converted shares. Sensei took the Faeth name and began trading as FTH on June 16.

PIKTOR holds FDA Fast Track designation in biomarker-selected advanced endometrial cancer, per the company. That is not an approval. Faeth plans a Phase 3 trial, subject to regulatory alignment.

Marvel Biosciences Reports MB-204 Data in Shank3 Autism Mouse Model

Marvel Biosciences (TSXV: MRVL; OTCQB: MBCOF) released final data from a Shank3 mouse study on November 10. The Shank3 Δex13-16 model is a mouse line that mirrors Phelan-McDermid syndrome, a genetic neurodevelopmental disorder.

At the higher oral dose, MB-204 brought six behavioral measures back to normal levels, including nose and paw contacts and Y-maze alternation scores. Istradefylline, MB-204’s parent compound, did not normalize those same six.

All of it is mouse data. MB-204 has not been tested in people. Marvel says it is preparing a Phase 1 trial but gave no start date.

The company is tiny. It had a market cap of about C$10.4 million in late April and closed a C$1.6 million private placement at C$0.15 per unit on September 29. The November 10 release also discloses paid investor-awareness deals: $50,000 to Outside The Box Capital and $45,000 to Investing News Network, both subject to TSXV acceptance. Neither arrangement has anything to do with aktiego.com.

EDSA, FTH, MRVL FAQ: Kyorin Upfront, Phase 3 Path, First Human Dosing

Does Kyorin’s $12 million upfront solve Edesa’s funding problem?

Not on its own. Edesa’s operating expenses were $5.5 million in the quarter ended June 30, so the upfront covers roughly two quarters at that pace, and the release gives no payment date. The $134 million in milestones depends on Japanese approval and pricing that are not assured.

TD Cowen says Faeth beat the chemo benchmark. Why did the stock halve?

Some investors had priced in a response rate near 40%, and 33% fell short. The data are preliminary, from a single-arm study with no control group, and the Phase 3 still needs regulatory alignment.

When does MB-204 reach a human trial?

Marvel says it is preparing a Phase 1 study but gave no start date in its November 10 release. Until that trial reads out, every efficacy result for MB-204 comes from mice.

Sources

Editorial Disclosure

Sources: company press releases (GlobeNewswire, BusinessWire, Newsfile), SEC Form 8-K summaries, named financial press. Press release dates verified: Edesa Biotech, November 9, 2026; Faeth Therapeutics, November 9, 2026; Marvel Biosciences, November 10, 2026. Securities discussed: Edesa Biotech, Inc. (Nasdaq: EDSA); Faeth Therapeutics, Inc. (Nasdaq: FTH); Marvel Biosciences Corp. (TSXV: MRVL; OTCQB: MBCOF). aktiego.com has received no compensation from any company, IR firm, or third party mentioned. No aktiego.com staff or principal holds a position in EDSA, FTH, MRVL, or MBCOF. Edesa Biotech: market value approximately $20.6 million per Benzinga before the November 9 move; paridiprubart is investigational and not approved in any market; Kyorin milestones and royalties are contingent and may never be paid; payment timing of the $12 million upfront not disclosed; Phase 3 data come from a study the company describes as truncated; roughly $25 million equity offering with warrants completed August 2026. Faeth Therapeutics: market cap approximately $568 million before the November 9 decline; PIK-201 results are preliminary, single-arm, and not controlled; PIK3CA-subgroup figures are a subset analysis; Fast Track designation is not an approval; current public listing results from a February 2026 stock-for-stock acquisition by Sensei Biotherapeutics, with former Faeth holders set to own about 89.3% before a concurrent $200 million private placement. Marvel Biosciences: market cap approximately C$10.4 million as of April 2026; elevated volatility and thin liquidity; MB-204 data are preclinical (mouse) only; no Phase 1 start date disclosed; repeated private placements at C$0.15 per unit; company disclosed paid investor-awareness agreements with Outside The Box Capital ($50,000) and Investing News Network ($45,000), unrelated to aktiego.com’s coverage. Each company covered is unprofitable, clinical or preclinical stage, and depend on continued access to capital. Small cap and micro-cap stocks listed on the CSE, TSX, TSXV, and Nasdaq are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.

Edesa Biotech Signs $12M Upfront Japan Deal With Kyorin

Faeth Therapeutics Falls as Much as 50% on 33% Response Rate

Marvel Biosciences Reports MB-204 Data in Shank3 Autism Mouse Model

EDSA, FTH, MRVL FAQ: Kyorin Upfront, Phase 3 Path, First Human Dosing

Sources

Editorial Disclosure

More Market Insights
on YouTube

The market moves fast.
Our briefing keeps up.

Edesa Biotech Licenses Paridiprubart to Kyorin for $12 Million Upfront

Edesa Biotech Signs $12M Upfront Japan Deal With Kyorin

Faeth Therapeutics Falls as Much as 50% on 33% Response Rate

Marvel Biosciences Reports MB-204 Data in Shank3 Autism Mouse Model

EDSA, FTH, MRVL FAQ: Kyorin Upfront, Phase 3 Path, First Human Dosing

Sources

Editorial Disclosure

Related Articles

More Market Insights on YouTube

The market moves fast.Our briefing keeps up.

More Market Insights
on YouTube

The market moves fast.
Our briefing keeps up.